PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Ziegler-Heitbrock, L. ; Frankenberger, M. ; Heimbeck, I. ; Burggraf, D. ; Wjst, M. ; Häussinger, K.* ; Brightling, C.* ; Gupta, S.* ; Parr, D.* ; Subramanian, D.* ; Singh, D.* ; Kolsum, U.* ; Boschetto, P.* ; Potena, A.* ; Gorecka, D.* ; Nowinksi, A.* ; Barta, I.* ; Döme, B.* ; Strausz, J.* ; Greulich, T.* ; Vogelmeier, C.* ; Bals, R.* ; Hohlfeld, J.* ; Welte, T.* ; Venge, P.* ; Gut, I.* ; Boland, A.* ; Olaso, R.* ; Hager, J.* ; Hiemstra, P.* ; Rabe, K.F.* ; Unmüßig, M.* ; Müller-Quernheim, J.* ; Prasse, A.*

The EvA study: Aims and strategy.

Eur. Respir. J. 40, 823-829 (2012)
Verlagsversion Volltext DOI PMC
Closed
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
The EvA study is an EU funded project (# 200506) under Frame Work Program 7 (FP7), which aims at defining new markers for COPD and its subtypes. The acronym is derived from emphysema versus airway disease, indicating that the project targets these two main phenotypes of the disease. The EvA study is based on the concept that emphysema and airway disease are governed by different pathophysiological processes and these are driven by different genes and a differential gene expression in the lung. To define these genes patients and non-COPD controls are recruited for clinical examination, lung function analysis and computed tomography of the lung. CT scans are used to define the phenotypes based on lung density and airway wall thickness. This is followed by bronchoscopy in order to obtain samples from the airways and the alveoli. These tissue samples along with blood samples are then subjected to genome-wide expression and association analysis and markers linked to the phenotypes are identified. The population of the EvA study is different from other COPD study populations, since patients with current oral glucocorticoid, antibiotics, exacerbations or current smoking are excluded, such that the signals detected in the molecular analysis are due to the distinct inflammatory process of emphysema and airway disease in COPD.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
5.895
2.270
9
23
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter no keywords
Sprache
Veröffentlichungsjahr 2012
HGF-Berichtsjahr 2012
ISSN (print) / ISBN 0903-1936
e-ISSN 1399-3003
Zeitschrift European Respiratory Journal
Quellenangaben Band: 40, Heft: 4, Seiten: 823-829 Artikelnummer: , Supplement: ,
Verlag European Respiratory Society
Verlagsort Sheffield
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Lung Health and Immunity (LHI)
POF Topic(s) 30503 - Chronic Diseases of the Lung and Allergies
30202 - Environmental Health
Forschungsfeld(er) Lung Research
PSP-Element(e) G-501690-001
G-501600-012
G-505000-003
PubMed ID 22441733
DOI 10.1183/09031936.00142811
Scopus ID 84867122301
Erfassungsdatum 2012-04-12
[➜Korrektur melden]